The ongoing SURPASS-CVOT trial (ClinicalTrials.gov registration no. NCT04255433) is expected to provide definitive answers on the impact of tirzepatide on cardiovascular disease compared with dulaglutide, a long-acting GLP-1 RA that has been shown to be cardioprotective in individuals with type 2 diabetes at increased cardiovascular risk [31]. Here, GLP1R is linked to type 2 diabetes mellitus.